Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 4/20 | 0.50 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.48 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.48 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 6/20 | 0.43 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.43 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.42 |
| ▸ | P2RY4 | P51582 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31342817 | 0.91 | DUT (0.48) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL2056795 | 0.91 | DUT (0.54) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL26757480 | 0.91 | DUT (0.54) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL26757474 | 0.91 | DUT (0.54) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL4314050 | 0.91 | DUT (0.54) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL7039715 | 0.91 | DUT (0.54) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL29431049 | 0.87 | DUT (0.56) | DUTP2RY2P2RY6P2RY14P2RY4 | |
| SCHEMBL25397715 | 0.84 | SLC28A1 (0.52) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL22300663 | 0.84 | SLC28A1 (0.52) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL23343339 | 0.84 | SLC28A1 (0.52) | DUTSLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 246 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122095093-A | RNAi agents for inhibiting expression of inhibin subunit beta E (INHBE), pharmaceutical compositions and methods of use | — | 2026-05-26 | — | — | CN | disclosed |
| US-20260103715-A1 | POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS INC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-4714500-A2 | HEPATITIS B VIRUS (HBV) DSRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2026-03-25 | — | — | EP | disclosed |
| US-12584130-B2 | Angiotensinogen (AGT) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-03-24 | — | — | US | disclosed |
| US-20260049312-A1 | COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS INC (US) | 2026-02-19 | — | — | US | disclosed |
| US-20260048130-A1 | ALPHA-V BETA-6 (avb6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ALNYLAM PHARMACEUTICALS INC (US) | 2026-02-19 | — | — | US | disclosed |
| EP-3837366-B1 | HEPATITIS B VIRUS (HBV) DSRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-12553053-B2 | Transmembrane serine protease 2 (TMPRSS2) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12551569-B2 | RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20260043025-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-02-12 | — | — | US | disclosed |
| US-20190024088-A1 | POLYNUCLEOTIDE AGENTS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12) AND METHODS OF USE THEREOF | Alnylam Phaarmaceuticals, Inc. (US) | 2019-01-24 | — | — | US | disclosed |
| US-20180371465-A1 | POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2018-12-27 | — | — | US | disclosed |
| US-20180208927-A1 | MULTI-TARGETED SINGLE ENTITY CONJUGATES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-07-26 | — | — | US | disclosed |
| US-20180201936-A1 | POLYNUCLEOTIDE AGENTS TARGETING PATATIN-LIKE PHOSPHOLIPASE DOMAIN CONTAINING 3 (PNPLA3) AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2018-07-19 | — | — | US | disclosed |
| US-20180187198-A1 | METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER | BANK OF AMERICA, N.A. | 2018-07-05 | — | — | US | disclosed |
| US-20180169129-A1 | POLYNUCLEOTIDE AGENTS TARGETING ANGIOTENSINOGEN (AGT) AND METHODS OF USE THEREOF | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-06-21 | — | — | US | disclosed |
| US-20180135057-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-05-17 | — | — | US | disclosed |
| US-20170240892-A1 | POLYNUCLEOTIDE AGENTS TARGETING SERPINC1 (AT3) AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2017-08-24 | — | — | US | disclosed |
| US-20170204418-A1 | POLYNUCLEOTIDE AGENTS TARGETING AMINOLEVULINIC ACID SYNTHASE-1 (ALAS1) AND USES THEREOF | BANK OF AMERICA, N.A. | 2017-07-20 | — | — | US | disclosed |
| US-20170183659-A1 | POLYNUCLEOTIDE AGENTS TARGETING COMPLEMENT COMPONENT C5 AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260049312-A1 | COMPLEMENT COMPONENT C3 IRNA COMPOSITIONS AND METHODS OF USE THEREOF | CFH, SSB, RNASEH1 | DUT 967/4885SLC28A1 1642/4885SLC28A2 1917/4885 |
| US-12553053-B2 | Transmembrane serine protease 2 (TMPRSS2) iRNA compositions and methods of use thereof | TMPRSS2, TMPRSS11D, TMPRSS4 | DUT 1583/4885SLC28A1 146/4885SLC28A2 68/4885 |
| US-20260043025-A1 | RNAi Agents And Compositions for Inhibiting Expression of Apolipoprotein C-III (APOC3) | APOB, APOL1, LDLR | DUT 185/4885SLC28A1 1102/4885SLC28A2 956/4885 |
| US-20180371465-A1 | POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOF | PDCD1LG2, CD274, PDCD1 | DUT 198/4885SLC28A1 676/4885SLC28A2 895/4885 |
| US-20180135057-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE LECT2 GENE | MCTS1, APOB, TTR | DUT 1734/4885SLC28A1 109/4885SLC28A2 22/4885 |
| US-12551569-B2 | RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use | MAPT, RNMT, NSUN2 | DUT 130/4885SLC28A1 1192/4885SLC28A2 829/4885 |
| US-20260048130-A1 | ALPHA-V BETA-6 (avb6) INTEGRIN LIGANDS FOR EXTRAHEPATIC DELIVERY | ITGB6, ITGA6, ITGA2B | DUT 1057/4885SLC28A1 1308/4885SLC28A2 1199/4885 |
| US-20180169129-A1 | POLYNUCLEOTIDE AGENTS TARGETING ANGIOTENSINOGEN (AGT) AND METHODS OF USE THEREOF | AGT, AGTR1, AGTR2 | DUT 180/4885SLC28A1 23/4885SLC28A2 28/4885 |
| US-20260103715-A1 | POLYNUCLEOTIDE AGENTS TARGETING PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) AND METHODS OF USE THEREOF | PDCD1LG2, CD274, PDCD1 | DUT 118/4885SLC28A1 715/4885SLC28A2 1132/4885 |
| US-20170183659-A1 | POLYNUCLEOTIDE AGENTS TARGETING COMPLEMENT COMPONENT C5 AND METHODS OF USE THEREOF | C5, C3AR1, NT5C3B | DUT 63/4885SLC28A1 442/4885SLC28A2 465/4885 |
| US-20180187198-A1 | METHODS AND COMPOSITIONS FOR TREATING A PROPROTEIN CONVERTASE SUBTILISIN KEXIN (PCSK9) GENE-ASSOCIATED DISORDER | PCSK9, PCSK7, PCSK6 | DUT 1783/4885SLC28A1 3181/4885SLC28A2 3295/4885 |
| US-12584130-B2 | Angiotensinogen (AGT) iRNA compositions and methods of use thereof | AGT, AGTR2, AGTR1 | DUT 280/4885SLC28A1 10/4885SLC28A2 6/4885 |
| US-20190024088-A1 | POLYNUCLEOTIDE AGENTS TARGETING FACTOR XII (HAGEMAN FACTOR) (F12) AND METHODS OF USE THEREOF | F12, F13A1, F11 | DUT 770/4885SLC28A1 2154/4885SLC28A2 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.